抗体-药物偶联物是一类新兴的抗癌药物，它将靶向抗体与有效的细胞毒性药物结合起来。与单克隆抗体或单独的细胞毒性化疗相比，它们的分子结构可以提高治疗效果并减少不良反应。抗体-药物偶联物通过多种机制引起脱靶毒性，包括血清中细胞毒性剂的过早解偶联以及正常组织上靶抗原的存在。鉴于在涉及抗体药物偶联物的临床试验中，皮肤不良事件占所有级别不良事件的 31.3%，因此越来越多的皮肤科医生被要求控制这些药物引起的皮肤毒性。在这篇综述中，我们总结了迄今为止已被美国食品和药物管理局批准使用的抗体药物缀合物的已知皮肤毒性。皮肤科医生可以在识别与抗体药物偶联物相关的皮肤反应、为其管理指南提供帮助以及在临床试验期间帮助生成抗体药物偶联物引起的皮肤毒性的详细形态学和组织病理学描述方面发挥关键作用。版权所有 © 2024。由爱思唯尔公司出版

Antibody-drug conjugates are an emerging class of anticancer agents that combine targeting antibodies with potent cytotoxic agents. Their molecular configuration allows for increased therapeutic efficacy and reduced adverse-effect profiles compared to monoclonal antibodies or cytotoxic chemotherapy alone. Antibody-drug conjugates cause off-target toxicities through several mechanisms, including premature deconjugation of the cytotoxic agent in the serum and the presence of the targeted antigen on normal tissues. Given cutaneous adverse events comprise 31.3% of all-grade adverse events in clinical trials involving antibody-drug conjugates, dermatologists are increasingly called upon to manage the cutaneous toxicities caused by these drugs. In this review, we summarize known cutaneous toxicities of the antibody-drug conjugates that have been approved for use by the U.S. Food and Drug Administration to date. Dermatologists can play a key role in recognizing cutaneous reactions associated with antibody-drug conjugates, contributing to guidelines for their management, and aiding during clinical trials to generate detailed morphologic and histopathologic descriptions of cutaneous toxicities caused by antibody-drug conjugates.Copyright © 2024. Published by Elsevier Inc.